Genetically modified Streptococcus thermophilus bacterium

US9040302B2 · kind B2 · utility

Assignees

• North Carolina State University · US
• University of Virginia Patent Foundation · US

Inventors

• Todd R. Klaenhammer · Raleigh, US
• Richard L. Guerrant · Charlottesville, US
• Glynis L. Kolling · Scottsville, US
• Evelyn Durmaz · Raleigh, US
• Michael Paul Timko · Charlottesville, US
• Cirle Alcantara Warren · Waynesboro, US

Key dates

• Filing date: May 19, 2011
• Grant date: May 26, 2015
• Expiry date: May 19, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2035/11
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.